Help us make childhood cancer universally survivable.
By giving monthly, you directly support our continued research into discovering effective and less toxic treatments for childhood cancer.
Support Our Lab
Our team is on a mission to make childhood cancer universally survivable!
The FDA approves on average 12 drugs every year to treat adult cancer, but has only approved 10 drugs to treat childhood cancer since 1978 (10 in 44 years for kids).
Since our inception in 2015, cc-TDI has pushed two drugs into three clinical trials to treat childhood cancer.
giving back childhood for
#GIVINGBACKCHILDHOOD
Latest News
Inspired Through Love
In March the Children’s Cancer Therapy Development Institute (cc-TDI) announced its partnership with Team KOODAC (Knock Out Oncogenic Drivers and Curing Childhood Cancer), a global interdisciplinary team of researchers, in which cc-TDI will receive up to $2.5 million over 5 years to develop novel protein degrader therapeutics to target previously undruggable drivers of children’s cancer primarily for rhabdomyosarcoma and secondarily for Ewing sarcoma. Today, we share the story behind the award and the lengths to which a father, inspired through love, has been instrumental in pushing cc-TDI’s research mission forward. Todd Georgopapadakos faced the unthinkable
cc-TDI’s 2023 Impact Report
cc-TDI Collaborates Globally with Atomwise
State of Oregon Awards $1M in Equipment
In the Press
Current Research Projects
A dedicated research team
Our research team is exploring and testing state-of-the-art treatment options for the most urgent issues facing children with cancer.
Working in our own freestanding research institution allows us to act swiftly and nimbly to achieve results—bringing cost control, speed, purpose, and focus to translate effective treatments into the clinic. To get there, we perform basic science and translational research in our industrial modern lab site (a paint factory remodeled by Nike as an off-site creative space), adjacent to the Silicon Forest in Oregon.